Nosso mais novo artigo internacional IEO-Milão

Enviado dia 10/09/2013 às 12:42:53


Caros amigos,
É com grande satisfação e  alegria que lhes compartilho nosso mais novo artigo internacional intitulado  "Locoregional recurrence in patients with HER2 positive breast cancer' na revista THE BREAST. Agradecemos especialmente o Dr. Bruno Achutti Duso, além dos Professores Aron Goldhirsch, Maria Cristina Leonardi, Roberto Orecchia e Giuseppe Curigliano do Instituto Europeu de Oncologia/Milão.
Janaina Brollo e Maximiliano Cassilha Kneubil




Literature shows that HER2/neu positive breast cancer cells are more sensitive to radiation-induced apoptosis by targeting the epidermal growth factor receptor family tyrosine kinase. We selected 466 patients with pT1-2 HER2/neu positive tumors who received adjuvant trastuzumab for primary invasive breast cancer. Patients were divided into three groups [Quadrantectomy followed by conventional radiotherapy vs Quadrantectomy followed by Intra-operative radiotherapy with electrons vs Mastectomy without radiotherapy]. After a median follow-up of 52 months, the 5-year cumulative incidence of locoregional recurrence (LRR) was 1.9%, 11.5% and 5.0% respectively (p < 0.01). At the multivariate analysis, extensive perivascular invasion, Luminal B HER2/Progesterone Receptor (PgR) negative status and Quadrantectomy followed by Intra-operative radiotherapy with electrons have significantly increased the risk of LRR. Our results suggest that HER2/neu positive breast cancer might have better outcomes when treated simultaneously with external radiotherapy and trastuzumab. Moreover, we underline the importance of PgR and further new stratification of risk among luminal subtypes.

Keywords: Breast cancer, Radiation therapy, Locoregional recurrence, HER2/neu, Trastuzumab

« Voltar
Oncomama - Oncologia Clínica

Caxias do Sul - RS
Rua Pinheiro Machado,2569- 3º andar
São Pelegrino - CEP: 95020-172

(54)3223.6107 | (54) 3221.1060